EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Primary Amphotericin B Monotherapy Versus Combination with Azoles or Echinocandins for Invasive Aspergillosis in Hematologic Malignancies: Comparable Outcomes over 22 Years in a Large Single-Center Cohort

Saliba Wehbe, Ray Hachem, Anne-Marie Chaftari, Amir Melek, Joanne Arvelaez Pascucci, Ying Jiang, Issam Raad

Journal of Fungi · 11.11.2026 · 12 (11) · 846

DOI: 10.3390/jof12110846 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Fungi, online erschienen am 11.11.2026. Verfasst von Saliba Wehbe und 6 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Invasive aspergillosis (IA) remains a major cause of mortality in patients with hematologic malignancies. Although combination antifungal therapy with lipid formulations of amphotericin B (AmB) plus an azole or echinocandin is widely used, its survival benefit over monotherapy remains uncertain.

Methods

We identified 912 patients with proven or probable IA diagnosed between January 2003 and October 2025, of whom 831 (91%) received ≥5 days of primary antifungal therapy. Among these, 305 patients who received an amphotericin B (AmB)-containing regimen were included in the study, including AmB monotherapy (n = 69), AmB plus an azole (n = 200), and AmB plus an echinocandin (n = 36). Inverse probability of treatment weighting (IPTW)-adjusted competing risks regression was used to assess the association between primary therapy (AmB monotherapy vs. combination therapy with an azole or echinocandin) and 6- and 12-week IA-related mortality.

Results

Multivariable competing risks analyses identified age ≥65 years, persistent neutropenia, and ICU admission as independent predictors of IA-related mortality. IPTW-adjusted analyses confirmed no significant association between treatment regimen and IA-related mortality.

Conclusions

Primary combination therapy was not associated with lower IA-related mortality than AmB monotherapy. Outcomes were driven primarily by disease severity markers, including older age, persistent neutropenia, and ICU admission.

Zitieren

APA

Wehbe, S., Hachem, R., Chaftari, A., Melek, A., Pascucci, J. A., Jiang, Y., & Raad, I. (2026). Primary Amphotericin B Monotherapy Versus Combination with Azoles or Echinocandins for Invasive Aspergillosis in Hematologic Malignancies: Comparable Outcomes over 22 Years in a Large Single-Center Cohort. Journal of Fungi, 12(11), 846. https://doi.org/10.3390/jof12110846

Vancouver

Wehbe S, Hachem R, Chaftari A, Melek A, Pascucci JA, Jiang Y, et al. Primary Amphotericin B Monotherapy Versus Combination with Azoles or Echinocandins for Invasive Aspergillosis in Hematologic Malignancies: Comparable Outcomes over 22 Years in a Large Single-Center Cohort. Journal of Fungi. 2026;12(11):846. doi:10.3390/jof12110846

BibTeX
@article{Wehbe2026,
  author = {Wehbe, Saliba and Hachem, Ray and Chaftari, Anne-Marie and Melek, Amir and Pascucci, Joanne Arvelaez and Jiang, Ying and Raad, Issam},
  title = {Primary Amphotericin B Monotherapy Versus Combination with Azoles or Echinocandins for Invasive Aspergillosis in Hematologic Malignancies: Comparable Outcomes over 22 Years in a Large Single-Center Cohort},
  journal = {Journal of Fungi},
  year = {2026},
  volume = {12},
  number = {11},
  pages = {846},
  doi = {10.3390/jof12110846}
}
Kostenlos starten →